In this study, we evaluated the viability, TE, and impact on HexA activity or physiological cell parameters of a CRISPR/nCas9 strategy involving transfection using the PP6D5 polymer as a novel non-viral vector in NIH-3T3 mouse embryonic fibroblasts, U87MG astrocytoma, SHSY5Y neuroblastoma, and human TSD fibroblasts (GM00515). This evidence concerns the gene HEXA and neuroblastoma.